CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

One particularly popular ETF is the Vanguard Value ETF (NYSEMKT: VTV). I do like it myself, but I'm a bit more jazzed by the ...

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

Investors in these popular ASX exchange-traded funds (ETFs) from the Vanguard stable enjoyed solid returns last financial ...

The largest transaction of the day was ARK’s acquisition of 102,806 shares of CRISPR Therapeutics AG (NASDAQ: CRSP ), valued at approximately $5.26 million. This purchase through the ARKK ETF reflects ...

If you're interested in broad exposure to the Large Cap Blend segment of the US equity market, look no further than the Vanguard Mega Cap ETF (MGC), a passively managed exchange traded fund launched ...

A high-level overview of CRISPR Therapeutics AG (CRSP) stock. View (CRSP) real-time stock price, chart, news, analysis, analyst reviews and more.

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.

Regenerative medicine is gaining serious momentum in 2025 as scientific advances, regulatory progress, and payer acceptance converge to push the sect ...